

Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



August 28, 2026

Company name: COSMOS Pharmaceutical Corporation
Name of representative: Hideaki Yokoyama, President
(Securities code: 3349; TSE Prime Market)
Contact: Motoi Takemori, Director and Corporate Planning Department Manager
(Phone: +81-92-433-0660)

View and Policy on Reduction of Investment Unit

1. View on reduction of investment unit

COSMOS Pharmaceutical Corporation (the “Company”) recognizes that lowering the investment unit is one of the effective measures to vitalize the stock market such as expanding the investor base and improving the liquidity of stocks.

2. Policy on reduction of investment unit

The Company will carefully consider lowering the investment unit, comprehensively taking into account its financial performance, stock price trends, the number and composition of shareholders, the liquidity of its stocks, and other factors.

* This disclosure is made in compliance with Rule 409 of the Securities Listing Regulations (Disclosure of Lowering Investment Units) as prescribed by the Tokyo Stock Exchange because the investment unit of the Company’s stocks was 500,000 yen or more as of May 31, 2026.